AgingResearch.News
AAIC 2025 Abstract

Characteristics and Safety Outcomes of Patients Treated with Lecanemab or Donanemab in Routine Clinical Practice: A Nationwide Study

By Jay B. Lusk, Kim G. Johnson, Andy J. Liu, Show 6 more authorsEmily Claire O'Brien
Study in peopleInterventions
Paper

Abstract

Background: Anti‐amyloid monoclonal antibodies (lecanemab and donanemab) received full approval by the FDA to treat early Alzheimer's disease and entered routine clinical practice in July 2023 and July 2024 respectively. Uptake patterns and post‐approval safety have not been fully characterized.

The paper

Jay B. Lusk, Kim G. Johnson, Andy J. Liu, Show 6 more authorsEmily Claire O'Brien

University of North Carolina at Chapel Hill; Duke University

AAIC 2025 Abstract, 23 Dec 2025, CC BY

Presented at AAIC 2025

doi.org/10.1002/alz70860_098805

Related